The Institute of Medical Genomics (IMEGEN) has been recognized as a Universitat de València’ spin-off. From now on, the academic institution will assist the company in its consolidation and will transfer knowledge in the biomedicine field that will be applied to diagnosis.
Universitat de València, through spin-off regulation and OTRI office, regulates the institutional assistance to companies coming from research or spin-off, at least during their first three years. It also preserves, being the owner, the rights of the resultos of research developed and it makes sure that its researchers’ business initiatives are carried out in accordance with the existing law and the intitution’s interests.
Located at Universitat de València’s Parc Científic, IMEGEN is an innovative, technology-based company whose main goal is the development and commercialization of products and analytic services in the moleculart diagnosis and human diseases prediction fields. Its activity is mainly aimed at human health and biomedicine sectors. Moreover, it develops several products and services of molecular diagnosis for the food and agriculture sector.
The company is headed by six biologists. Its chairman is Manuel Pérez Alonso, a tenured lecturer of genetics at Universitat de València, where he also founded the Laboratorio de Genética Molecular del Desarrollo. He has developed more than twenty research projects and three biotechnological patents for the pharmaceutical industry. He has collaborated in three international consortium of genomes sequencing. ‘It is important for scientist to be aware of the vital task that is transfering knowledge to society’ states Pérez Alonso.
Last update: 30 de march de 2012 16:21.
News release
